Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma

NCT05169515 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05169515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05169515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 26, 2022
Completion date
August 5, 2029
Enrollment
121 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma